Preferred Label : Anti-DR5 Agonistic Monoclonal Antibody INBRX-109;
NCIt definition : A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against
human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic
and antineoplastic activities. Upon administration, INBRX-109 specifically binds to
exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with
its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway,
which results in the activation of caspase cascades, the induction of tumor cell apoptosis
and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent
monoclonal antibody may overcome the challenge of generating effective DR5 clustering
while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering.
DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces
of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.;
Molecule name : INBRX 109; INBRX-109;
NCI Metathesaurus CUI : CL936041;
Origin ID : C157062;
UMLS CUI : C4745246;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
